Global Commercial Strategy (GCS): Senior Manager, Early GI, Rheumatology, and Neurology

Why Patients Need You

Everything we do, every day, is driven by an unwavering commitment to the patients, healthcare providers, and customers who depend on us. In Global Commercial Strategy (GCS), we translate science of R&D into value for patients and Pfizer — from early development through launch, growth, and LOE lifecycle. GCS serves as the strategic engine and commercial voice across the asset lifecycle — shaping asset positioning and evidence generation, leading global launches, and driving sustained access and brand performance through market and payer insights, broad access, & commercial rigor. We take pride in shaping how innovative medicines reach the people who need them most, and ensuring they are accessible, understood, and valued across every market. Our success is anchored in the following Pfizer Blueprint values: Science, Technology, Transformation and Colleagues. Whether you are defining strategy, managing brands at different lifecycle, or building the capabilities that power our commercial engine, your work directly shapes patient outcomes and the long-term success of Pfizer's portfolio.

Role Summary:

The Senior Manager, Early Commercial Rheumatology, GI, and Neurology is a key role within the Inflammation & Immunology (I&I) Early Commercial Business, part of the Global Commercial Strategy organization, reporting to the I&I Disease Area Lead. This role will include contributing to long-range commercial strategy, disease-area portfolio prioritization, early commercial assessments, and investment decision support across Rheumatology, GI, and Neurology priorities within the I&I portfolio.

The broader I&I and Rare Disease portfolio represents significant strategic value to realizing Pfizer's vision to achieve leadership via breakthroughs in prioritized diseases and biological axes, with the goal of generating highly differentiated, multi-indication mega-blockbusters. Today, the portfolio delivers more than $10B globally, with 22 ongoing clinical studies underway to significantly expand the product portfolio over the next several years. This role will help translate that ambition into clear disease-area strategies, disciplined portfolio choices, and integrated commercial plans that maximize patient impact and enterprise value.

This leader will serve as the asset-level commercial voice for a subset of the assigned disease areas, bringing scientific depth, commercial judgment, and enterprise perspective to shape early development choices, product concepts, external innovation opportunities, and future value creation. The Senior Director will partner closely with R&D, Medical Affairs, Global

Access Strategy & Pricing (GASP), Business Analytics & Insights, Competitive Intelligence, Business Development, and US and International Commercial teams to translate scientific, clinical, market, access, and competitive insights into clear portfolio recommendations and actionable strategic choices.

This role requires a commercial strategist who can operate across ambiguity, influence senior cross-functional stakeholders, and advance disciplined trade-off decisions, long-range portfolio thinking, and AI-enabled ways of working in support of patient impact and enterprise value realization.

Responsibilities:

Disease Area Strategy and Long-Range Planning:

· Support development of long-range commercial and portfolio strategy across a subset of Rheumatology, GI, and Neurology disease areas, spanning early pipeline assets, lifecycle opportunities, external innovation, and emerging disease-area opportunities.

· Support generation of integrated near-, mid-, and long-term views of disease-area opportunities, risks, and investment priorities to inform portfolio decision-making.

· Synthesize scientific, clinical, commercial, access, competitive, and patient insights to identify priority opportunities and strategic trade-offs.

· Monitor shifts in the scientific and competitive landscape to identify emerging trends, market discontinuities, and implications for future I&I strategy.

· Translate disease-area strategy into clear recommendations, implications, and decision materials for leadership, governance forums, and cross-functional portfolio discussions.

Portfolio Prioritization and Investment Decision Support:

· Provide commercial leadership for portfolio prioritization, investment choices, and development opportunities across assigned disease areas.

· Pressure-test commercial assumptions, value drivers, risks, uncertainties, and evidence needs that may influence future launch potential, lifecycle value, and portfolio performance.

· Lead development of executive-ready materials that communicate strategic rationale, opportunity attractiveness, trade-offs, and recommended actions.

· Partner with cross-functional leaders to align on key choices related to indication sequencing, evidence generation, market development, and lifecycle opportunities.

…